ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      58,653.95
      1.32%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. AbbVie Inc (ABBV)

      7. AbbVie Inc (ABBV) News

      ABBV

      AbbVie (ABBV)

      AbbVie Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:ABBV
      DateTimeSourceHeadlineSymbolCompany
      02/20/20245:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      02/20/20245:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      02/20/20245:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      02/20/20245:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      02/20/20245:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      02/20/20245:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      02/20/20245:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      02/20/20245:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      02/20/20245:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      02/20/20249:00AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
      02/20/20249:00AMPR Newswire (US)AbbVie Announces Appointment of Robert A. Michael as Chief Executive OfficerNYSE:ABBVAbbVie Inc
      02/19/20248:30AMPR Newswire (US)AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)NYSE:ABBVAbbVie Inc
      02/15/202412:03PMPR Newswire (US)AbbVie Declares Quarterly DividendNYSE:ABBVAbbVie Inc
      02/12/20247:49AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
      02/12/20247:37AMPR Newswire (US)AbbVie Completes Acquisition of ImmunoGenNYSE:ABBVAbbVie Inc
      02/08/20248:00AMPR Newswire (Canada)VYALEVMC (solution de foslévodopa/foscarbidopa), médicament d'AbbVie, offert au Canada pour le traitement de la maladie de Parkinson à un stade avancéNYSE:ABBVAbbVie Inc
      02/08/20248:00AMPR Newswire (Canada)AbbVie's VYALEV™ (foslevodopa/foscarbidopa solution) Available for the Treatment of Advanced Parkinson's Disease in CanadaNYSE:ABBVAbbVie Inc
      02/06/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
      02/06/202412:00PMPR Newswire (US)Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseasesNYSE:ABBVAbbVie Inc
      02/02/20245:50PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABBVAbbVie Inc
      02/02/20247:51AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
      02/02/20247:36AMPR Newswire (US)AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial ResultsNYSE:ABBVAbbVie Inc
      01/31/202411:00AMPR Newswire (US)Allergan Aesthetics Releases "Decoding the Future of Aesthetic Individuality" Exploring the Power of Self-ExpressionNYSE:ABBVAbbVie Inc
      01/25/20243:00AMPR Newswire (US)Allergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024NYSE:ABBVAbbVie Inc
      01/23/20248:00AMPR Newswire (US)Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.NYSE:ABBVAbbVie Inc
      01/11/20246:18AMIH Market NewsWall Street Highlights: Mastercard’s Financial Rise, Citigroup’s $3.8 Billion Charges, and MoreNYSE:ABBVAbbVie Inc
      01/09/20242:00AMPR Newswire (US)AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European UnionNYSE:ABBVAbbVie Inc
      01/08/20249:16AMDow Jones NewsAbbVie to Move Lutikizumab Into Phase 3 in Hidradenitis SuppurativaNYSE:ABBVAbbVie Inc
      01/08/20248:05AMPR Newswire (US)Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3NYSE:ABBVAbbVie Inc
      01/05/20244:03PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
       Showing the most relevant articles for your search:NYSE:ABBV